Safe and Efficacious Use of a Topical Retinoid Under Occlusion for the Treatment of Mycosis Fungoides
December 2014 | Volume 13 | Issue 12 | Editorials | 1479 | Copyright © 2014
Daniel Aires MD JD,a Tarek Shaath BS,c Garth Fraga MD,b
Anand Rajpara MD,a Ryan Fischer MD,a Deede Liu MD,a
aUniversity of Kansas Medical Center, Department of Internal Medicine,
Division of Dermatology, Kansas City, KS
bUniversity of Kansas Medical Center, Department of Pathology, Kansas City, KS
cUniversity of Kansas School of Medicine, Kansas City, KS
No abstract available
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Oral and topical retinoids are widely used for treating Mycosis Fungoides (MF), the most common form of cutaneous t-cell lymphoma (CTCL).1,2 While the retinoid- X-receptor-selective bexarotene is the only topical retinoid approved for MF, other retinoids such as tretinoin have also been used.3 As with all topical retinoids, both bexarotene and tretinoin typically cause mild-to-moderate local irritation.4,5 This irritation may be reduced by alternating retinoid treatment with mid-potency topical corticosteroid treatment. Use of topical steroids may also bring synergistic benefits in conjunction with retinoids.6 An added benefit of combination treatment arises from the fact that steroid-associated skin atrophy can potentially be mitigated by concomitant retinoid usage.7
Retinoids under occlusion have been tried used in various settings other than MF. Stam-Posthuma et al attempted unsuccessfully to treat nevi with tretinoin and/or hydrocortisone under occlusion.8 Watson et al reported use of 0.025% all-trans retinoic acid under occlusion to treat photoaging.9 Fisher et al explored tretinoin under occlusion for prevention of photodamage.10
We present the first report of MF treated with combined steroid and retinoid wraps. A 76-year-old Caucasian male with folliculotropic MF presented to an academic outpatient dermatology clinic for further management of skin-directed therapy. Physical exam revealed scaly, erythematous papules and plaques with follicular prominence distributed over the trunk and extremities. Fevers, night sweats, and lymphadenopathy were absent. Flow cytometry showed an elevated CD4:CD8 ratio of approximately 30:1. Treatments at time of presentation included topical triamcinolone and clobetasol twice daily to affected areas on the trunk and limbs, as well as interferon alfa 2b three million units subcutaneously biweekly, and extracorporeal photopheresis (ECP) every other week. The systemic treatment regimen did not change during the duration of the case reported here.
At time of presentation most cutaneous lesions were responding to therapy, with the exception of a few resistant raised firm scaly erythematous plaques on the chest, arms and legs. To address this, a new regimen was tried initially on a single resistant plaque on the right calf (Figure 1). An occlusive Unna wrap was applied to the right calf over a layer of 0.1% tazarotene gel and a layer of 0.1% triamcinolone ointment. The initial wrap stayed in place until the patient’s follow up examination two weeks later. At that time the resistant plaque showed decreased erythema and scaling with no local or systemic side effects. Despite the good initial response, the patient chose to switch over to a more convenient and affordable regimen of 0.1% tretinoin and 0.05% clobetasol under plastic-wrap occlusion to be applied at home. Specifically, the patient applied a fresh plastic-wrap dressing each night, alternating tretinoin wraps with clobetasol wraps. Follow up appointments at two-week intervals demonstrated continued improvement in the patient’s resistant folliculotropic MF plaque. Treatment was continued for 22 more weeks without any adverse side effects or patient complaints. By that time the patient’s right lower extremity plaque had become significantly flatter and smoother, similar in appearance to his non-resistant lesions (Figure 2). Based on this response, other resistant plaques were subsequently treated in the same way.
Skin-directed MF therapies typically include steroids,11 retinoids,1 mechlorethamine,12 phototherapy,13 and radiotherapy. 14 Folliculotropic MF is generally considered to be more resistant to topical therapies.15 If MF plaques are resistant to these topical therapies, systemic treatment may be considered. Systemic MF / CTCL treatments include photopheresis,16 oral retinoids,2 histone deacetylase inhibitors,17 denileukin diftitox,18 and ultimately conventional chemotherapy.
The present case demonstrated tolerability and efficacy of topical retinoids under occlusion combined with topical